KASINGER JAMES R. sold $119K of CRSP

KASINGER JAMES R. (General Counsel and Secretary) sold 1,990 shares of CRISPR Therapeutics AG (CRSP) at $60.04 ($0.12M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KASINGER JAMES R.
Published Oct 8, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRSP
Neutral
high confidence
Mentioned
$CRSP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPNeutralLow
01

Why it matters

The sale represents a routine liquidity event with limited market impact.

02

Market read

A modest insider sale filed today; unlikely to affect price materially.

03

What to watch

The sale was executed under a 10b5-1 plan, which removes speculation about timing motives.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

Form 4 filings disclose insider transactions and are primary sources for insider activity.

Company-level read

Ticker impact

$CRSPNeutralHigh confidence
Context

General Counsel James R. Kasinger sold 1,990 shares for $119,481 via a 10b5-1 plan, reducing his stake to 94,784 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

The transaction size is small relative to total float and follows a pre‑arranged plan, indicating no new negative information about the company.

Market effects

Minimal impact on the biotech sector; insider sales are routine.

None

None

Counterpoint

If the insider had a larger stake, the sale could be seen as a lack of confidence, but the modest size suggests routine liquidity needs.

Key entities

  • James R. Kasinger

    General Counsel and Secretary of CRISPR Therapeutics AG

  • CRISPR Therapeutics AG

    Biotech firm developing CRISPR gene‑editing therapies

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.

$CRSPMedAI 8/10

CRISPR Therapeutics reports trial results for gene therapy CTX310

CRISPR Therapeutics (CRSP) reported Phase 1b trial results for CTX310, a gene therapy for severe hypertriglyceridemia. The trial showed significant reductions in triglycerides, ANGPTL3 protein, and other cholesterol markers. No serious adverse events were reported. The FDA has granted RMAT designations to CTX310 for this indication and for elevated LDL cholesterol.